Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease
Exploring the Efficacy and Biobehavioural Basis of Baclofen in the Treatment of Alcoholic Liver Disease
Sponsor: National Health and Medical Research Council, Australia
This PHASE3 trial investigates Alcohol Dependence and Alcoholic Liver Disease and is currently completed. National Health and Medical Research Council, Australia leads this study, which shows 6 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
▶ Show 1 earlier version
-
Jan 2017 — Aug 2017 [monthly]
Unknown Status PHASE3
First recorded
Mar 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Health and Medical Research Council, Australia
- South West Sydney Local Health District
- University of Sydney
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Sydney, Australia